Importantly, semaglutide carries a boxed warning for risk of thyroid C-cell tumors, and is contraindicated in patients with a personal or family history of medullary thyroid carcinoma (MTC) or in patients with Multiple Endocrine Neoplasia syndrome type 2 (MEN2)
Food and Drug Administration (FDA) for long-term weight management in adults with obesity or overweight conditions related to other health issues
Do we have clear escalation pathways to clinical staff for red-flag symptoms
Wegovy, a higher-dose formulation of semaglutide, is specifically approved for weight management
Medication $349-$1,000+ per month Initial visit $50-$300 Follow-up visits $75-$150 every 1-3 months Labs $100-$300 initially and then every 3-6 months Plus supplies (e.g., alcohol swabs, pen needles/syringes, and sharps disposal) Adults, aged 18 or older, with BMI 30 kg/m 2 or 27 kg/m 2 with weight-related conditions (e.g., type 2 diabetes, hypertension) may qualify
Obesity also raises the risk of conditions such as obstructive sleep apnoea, obesity hypoventilation syndrome, and cardiovascular disease, all of which can worsen breathlessness
